Aardvark Therapeutics, Inc.
AARD
$8.22
-$0.30-3.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -109.92% | -9.66% | 0.00% | -86.84% | 3.22% |
| Total Depreciation and Amortization | -239.08% | 248.00% | 0.00% | 134.72% | -376.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.69% | 48.43% | 0.00% | -39.54% | -67.69% |
| Change in Net Operating Assets | 948.96% | -122.48% | 0.00% | -38.47% | 319.62% |
| Cash from Operations | -95.37% | -23.50% | 0.00% | -177.03% | 27.07% |
| Capital Expenditure | -20.00% | 89.80% | 0.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -237,800.00% | 89.80% | 0.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -3.55% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | 0.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,020.95% | 89.80% | 0.00% | -- | -- |
| Cash from Financing | -1,684.38% | -99.85% | 0.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -429.67% | -110.19% | 0.00% | 3,406.14% | 27.07% |